UiPath enters the week with a striking contradiction at its core — short interest near the highest level in its history, yet options traders are the most bullish they have been all year.
The options signal is the sharpest data point this week. The put/call ratio dropped to 0.46, more than two standard deviations below its 20-day average of 0.57, and close to the 52-week low of 0.22. That means call buying is dominating options flow at an unusual clip — a level of bullish positioning that stands out against a backdrop where 30% of the free float is sold short. The divergence is not subtle. Over the past month PATH has rallied 17% to $12.04, and the options market appears to be chasing that momentum rather than hedging against further gains.
The short interest picture tells a more complicated story. At 30.5% of the free float, the short position is substantial by any measure, and it jumped roughly 10 percentage points around July 10 — a meaningful step-up over just a few sessions. Yet the borrow market has not tightened to match. Availability is running at 110%, meaning lenders are offering roughly as many shares as are currently short — a notably loose condition for a stock this heavily positioned. Cost to borrow has also eased, falling 25% over the past month to around 0.53%. The ORTEX short score is elevated at 67, but has drifted lower every day this week, suggesting some of the short-side pressure is beginning to ease. The borrow market, in short, does not look squeezed — there is no mechanical pressure forcing shorts to cover.
The Street remains broadly cautious, though targets sit close to the current price. The mean analyst target is $13.25, implying only modest upside from $12.04. Recent analyst activity has been mostly downward — UBS lowered its target to $12 in late June, while Morgan Stanley and BMO trimmed theirs after the last earnings print. Bank of America is the outlier, raising its target to $13 while maintaining an Underperform rating. That sums up the analyst mood neatly: the stock looks fairly valued to slightly cheap at current levels, but conviction is low. The EV/EBITDA multiple has drifted down to 9.7x over the past month even as the price rallied, reflecting improving earnings rather than multiple expansion. The forward earnings rank sits in the 9th percentile of the universe — weak — and the short score ranks in just the 7th percentile, confirming that the fundamental story remains pressured.
The bull and bear cases are well defined. Bulls point to 14% revenue growth, $1.853 billion in ARR growing 11% year-on-year, and RPO up 19% — a backlog that provides some visibility. Bears focus on dollar-based net revenue retention slipping to 107%, limited margin expansion, and the risk that AI-native workflow tools erode UiPath's automation franchise before it can reposition. The recent WorkFusion acquisition adds integration risk. Most peers traded modestly positive on the week — WDAY and DOCU each gained roughly 1-3% — while PATH edged up less than 1%, suggesting the market is not yet rewarding the revenue momentum story with a premium.
Insider activity is worth a brief note. The CFO, CTO, and General Counsel all sold shares on July 1 at $10.87 — a coordinated cluster of routine-looking sales, all at low significance scores, but notable timing given the stock's subsequent 10% move higher. The founder and CEO Daniel Dines remains by far the largest holder at nearly 20% of shares, a structural anchor that limits float.
The next scheduled earnings release is September 2. Between now and then, the key tension to watch is whether the call-buyer enthusiasm in options survives contact with a short base that has not meaningfully covered — and whether availability remains loose enough to keep borrow costs from becoming a catalyst of their own.
See the live data behind this article on ORTEX.
Open PATH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
